PSS10 - A Us Hospital Economic Impact Model for Oritavancin In Absssi Patients With Risk of Mrsa Infections
470. Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Significant Drug Abuse: Outcomes from Global Phase 3 Studies of Delafloxacin (DLX)
